1. Home
  2. WEX vs ORKA Comparison

WEX vs ORKA Comparison

Compare WEX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WEX

WEX Inc. common stock

N/A

Current Price

$181.09

Market Cap

6.5B

ML Signal

N/A

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

N/A

Current Price

$106.56

Market Cap

6.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WEX
ORKA
Founded
1983
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.4B
IPO Year
2004
1997

Fundamental Metrics

Financial Performance
Metric
WEX
ORKA
Price
$181.09
$106.56
Analyst Decision
Buy
Strong Buy
Analyst Count
15
13
Target Price
★ $202.09
$156.17
AVG Volume (30 Days)
602.1K
★ 994.1K
Earning Date
10-28-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.93
N/A
EPS
★ 9.20
N/A
Revenue
★ $2,660,800,000.00
N/A
Revenue This Year
$11.90
N/A
Revenue Next Year
$2.45
N/A
P/E Ratio
$19.49
★ N/A
Revenue Growth
★ 1.24
N/A
52 Week Low
$125.29
$25.23
52 Week High
$203.99
$115.52

Technical Indicators

Market Signals
Indicator
WEX
ORKA
Relative Strength Index (RSI) 47.79 67.48
Support Level $148.03 $83.25
Resistance Level $189.61 $115.52
Average True Range (ATR) 7.00 5.87
MACD -0.58 1.30
Stochastic Oscillator 32.27 70.58

Price Performance

Historical Comparison
WEX
ORKA

About WEX WEX Inc. common stock

WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: